In vitro effects of the chemotherapy agent water-soluble micellar paclitaxel (Paccal Vet) on canine hemangiosarcoma cell lines
作者： Caroline R. Reckelhoff , Amandine Lejeune , Patrick M. Thompson , Keijiro Shiomitsu
DOI: 10.1111/VCO.12442
关键词:
摘要: Paccal Vet (Osamia Pharmaceuticals) is a water-soluble nanoparticle micellar formulation of the drug paclitaxel that well tolerated in dogs. This study evaluated vitro effect on two canine hemangiosarcoma (HSA) cell lines and their expression vascular endothelial growth factor (VEGF) basic fibroblast (bFGF). caused HSA death dose- time-dependent manner. The 50% inhibitory concentration (IC50 ) for were 7 to 610 ng/mL, which are clinically achievable. Cell cycle analysis through flow cytometry showed arrest at G2/M phase. Annexin-V caspase 3/7 activity assays significant increases apoptosis correlation with IC50 each line. Reverse transcriptase-PCR was performed validate gene VEGF bFGF. Results obtained from this support future studies involving use (micellar) treatment HSA.
sci-hub.se 参考文章(45)
Kathy Kamath, Greg Smiyun, Leslie Wilson, Mary Ann Jordan, Mechanisms of inhibition of endothelial cell migration by taxanes Cytoskeleton. ,vol. 71, pp. 46- 60 ,(2014) , 10.1002/CM.21153
C. Khanna, M. Rosenberg, D. M. Vail, A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs. Journal of Veterinary Internal Medicine. ,vol. 29, pp. 1006- 1012 ,(2015) , 10.1111/JVIM.12596
Heather L. Gardner, Cheryl A. London, Roberta A. Portela, Sandra Nguyen, Mona P. Rosenberg, Mary K. Klein, Craig Clifford, Douglas H. Thamm, David M. Vail, Phil Bergman, Martin Crawford-Jakubiak, Carolyn Henry, Jennifer Locke, Laura D. Garrett, Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma BMC Veterinary Research. ,vol. 11, pp. 131- 131 ,(2015) , 10.1186/S12917-015-0446-1
S. E. Lyles, R. J. Milner, K. Kow, M. E. Salute, In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Veterinary and Comparative Oncology. ,vol. 10, pp. 223- 235 ,(2012) , 10.1111/J.1476-5829.2012.00335.X
R. Finotello, D. Stefanello, E. Zini, L. Marconato, Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Veterinary and Comparative Oncology. ,vol. 15, pp. 25- 35 ,(2017) , 10.1111/VCO.12139
K. Marley, C. S. Maier, S. C. Helfand, Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma. Veterinary and Comparative Oncology. ,vol. 10, pp. 214- 222 ,(2012) , 10.1111/J.1476-5829.2012.00325.X
Henrik Von Euler, Patricio Rivera, Helena Nyman, Jens Häggström, O Borgå, None, A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. Veterinary and Comparative Oncology. ,vol. 11, pp. 243- 255 ,(2013) , 10.1111/J.1476-5829.2011.00314.X
A. Khammanivong, B. H. Gorden, A. M. Frantz, A. J. Graef, E. B. Dickerson, Identification of drug-resistant subpopulations in canine hemangiosarcoma. Veterinary and Comparative Oncology. ,vol. 14, ,(2016) , 10.1111/VCO.12114
Kristin M. Wendelburg, Lori Lyn Price, Kristine E. Burgess, Jeremiah A. Lyons, Felicia H. Lew, John Berg, Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). Javma-journal of The American Veterinary Medical Association. ,vol. 247, pp. 393- 403 ,(2015) , 10.2460/JAVMA.247.4.393
Douglas Bates, Martin Mächler, Ben Bolker, Steve Walker, Fitting Linear Mixed-Effects Models Using lme4 Journal of Statistical Software. ,vol. 67, pp. 1- 48 ,(2015) , 10.18637/JSS.V067.I01